Avanos Medical, Inc.
AVNSNYSEHealthcare● Active
$25.02
$-0.04(-0.14%)
Market Cap$1.2B
P/E Ratio—
52W High$25.49
52W Low$9.303
Avanos Medical, Inc. (AVNS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AVNS · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
$0.22
Est. $0.16 · +37.5%
Revenue
$0.18B
Est. $0.17B · +7.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 3-Quarter EPS Beat Streak
AVNS reports quarterly as a NYSE-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | $0.16 | — | — | — | $0.17B | — |
| ▲ Q2 FY2026 | May 5, 2026 | $0.16 | $0.22 | +37.5% | $0.18B | $0.17B | +7.2% |
| ▲ Q1 FY2026 | Feb 24, 2026 | $0.24 | $0.29 | +20.8% | $0.18B | $0.17B | +3.5% |
| ▲ Q4 FY2025 | Nov 5, 2025 | $0.12 | $0.22 | +83.3% | $0.18B | $0.16B | +8.1% |
| ▼ Q3 FY2025 | Aug 5, 2025 | $0.18 | $0.17 | -5.6% | $0.17B | $0.17B | +4.5% |
| ▲ Q2 FY2025 | May 6, 2025 | $0.19 | $0.26 | +36.8% | $0.17B | $0.17B | -0.5% |
| ▲ Q1 FY2025 | Feb 26, 2025 | $0.40 | $0.43 | +7.5% | $0.18B | $0.17B | +4.1% |
| — Q4 FY2024 | Oct 30, 2024 | $0.36 | $0.36 | +0.0% | $0.17B | $0.18B | -3.9% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
$0.16
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Beat
EPS Actual
$0.22
EPS Est.
$0.16
EPS Surpr.
+37.5%
Revenue
$0.18B
Q1 FY2026
Feb 24, 2026Beat
EPS Actual
$0.29
EPS Est.
$0.24
EPS Surpr.
+20.8%
Revenue
$0.18B
Q4 FY2025
Nov 5, 2025Beat
EPS Actual
$0.22
EPS Est.
$0.12
EPS Surpr.
+83.3%
Revenue
$0.18B
Q3 FY2025
Aug 5, 2025Miss
EPS Actual
$0.17
EPS Est.
$0.18
EPS Surpr.
-5.6%
Revenue
$0.17B
Q2 FY2025
May 6, 2025Beat
EPS Actual
$0.26
EPS Est.
$0.19
EPS Surpr.
+36.8%
Revenue
$0.17B
Q1 FY2025
Feb 26, 2025Beat
EPS Actual
$0.43
EPS Est.
$0.40
EPS Surpr.
+7.5%
Revenue
$0.18B
Q4 FY2024
Oct 30, 2024
EPS Actual
$0.36
EPS Est.
$0.36
EPS Surpr.
+0.0%
Revenue
$0.17B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.34 | $0.34 | $0.34 | 1 |
| Q3 FY2027 | $0.32 | $0.32 | $0.32 | 1 |
| Q2 FY2027 | $0.30 | $0.30 | $0.30 | 1 |
| Q1 FY2027 | $0.29 | $0.29 | $0.29 | 1 |
| Q4 FY2026 | $0.37 | $0.37 | $0.37 | 1 |
| Q3 FY2026 | $0.33 | $0.33 | $0.33 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.2B | $0.2B | $0.2B | 1 |
| Q3 FY2027 | $0.2B | $0.2B | $0.2B | 1 |
| Q2 FY2027 | $0.2B | $0.2B | $0.2B | 1 |
| Q1 FY2027 | $0.2B | $0.2B | $0.2B | 1 |
| Q4 FY2026 | $0.2B | $0.2B | $0.2B | 1 |
| Q3 FY2026 | $0.2B | $0.2B | $0.2B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 5, 2026 | +37.5% | $24.66 | $24.70 | +0.16% |
| ▲ Q1 FY2026 | Feb 24, 2026 | +20.8% | $15.23 | $13.64 | -10.44% |
| ▲ Q4 FY2025 | Nov 5, 2025 | +83.3% | $11.30 | $10.66 | -5.66% |
| ▼ Q3 FY2025 | Aug 5, 2025 | -5.6% | $11.25 | $9.89 | -12.09% |
| ▲ Q2 FY2025 | May 6, 2025 | +36.8% | $12.19 | $12.85 | +5.41% |
| ▲ Q1 FY2025 | Feb 26, 2025 | +7.5% | $15.56 | $15.62 | +0.39% |
| ▲ Q4 FY2024 | Oct 30, 2024 | +0.0% | $22.63 | $18.58 | -17.90% |
| ▲ Q3 FY2024 | Jul 31, 2024 | +17.2% | $22.96 | $23.92 | +4.18% |
Q2 FY2026+0.16%
Report Date
May 5, 2026
EPS Beat/Miss
+37.5%
Price Before
$24.66
Price After
$24.70
Q1 FY2026-10.44%
Report Date
Feb 24, 2026
EPS Beat/Miss
+20.8%
Price Before
$15.23
Price After
$13.64
Q4 FY2025-5.66%
Report Date
Nov 5, 2025
EPS Beat/Miss
+83.3%
Price Before
$11.30
Price After
$10.66
Q3 FY2025-12.09%
Report Date
Aug 5, 2025
EPS Beat/Miss
-5.6%
Price Before
$11.25
Price After
$9.89
Q2 FY2025+5.41%
Report Date
May 6, 2025
EPS Beat/Miss
+36.8%
Price Before
$12.19
Price After
$12.85
Q1 FY2025+0.39%
Report Date
Feb 26, 2025
EPS Beat/Miss
+7.5%
Price Before
$15.56
Price After
$15.62
Q4 FY2024-17.90%
Report Date
Oct 30, 2024
EPS Beat/Miss
+0.0%
Price Before
$22.63
Price After
$18.58
Q3 FY2024+4.18%
Report Date
Jul 31, 2024
EPS Beat/Miss
+17.2%
Price Before
$22.96
Price After
$23.92
Avg Beat Reaction-3.41%
Avg Miss Reaction-12.09%
Beat Rate7 / 8 quarters
Largest Move-17.90% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AVNS ends December
Avanos Medical, Inc. (AVNS) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $0.22 — beating the analyst consensus of $0.16 by +37.5%. AVNS has beaten EPS estimates for 3 consecutive quarters. The next AVNS earnings date is expected around September 1, 2026.
Each quarter, investors track AVNS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AVNS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AVNS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AVNS earnings · 5 questionsAvanos Medical, Inc.'s next earnings report is expected around September 1, 2026. AVNS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AVNS historically reports after market close (AMC).
AVNS earnings datewhen is AVNS earningsAVNS next earnings datewhen does AVNS report earningsAVNS earnings calendar
▸ Source: FMP · Avanos Medical, Inc. SEC filings · US GAAP · Avanos Medical, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026